Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.

Journal of medical genetics - 1 May 2020

Leonard Hampton, Blauwendraat Cornelis, Krohn Lynne, Faghri Faraz, Iwaki Hirotaka, Ferguson Glen, Day-Williams Aaron G, Stone David J, Singleton Andrew B, Nalls Mike A, Gan-Or Ziv

Abstract excerpt

BACKGROUND: Classical randomisation of clinical trial patients creates a source of genetic variance that may be contributing to the high failure rate seen in neurodegenerative disease trials. Our objective was to quantify genetic difference between randomised trial arms and determine how imbalance can affect trial outcomes. METHODS: 5851 patients with Parkinson's disease of European ancestry data and two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Variation
Share to Models, Statistical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neurodegenerative Diseases

Share to Parkinson Disease

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 31784483
DOI: 10.1136/jmedgenet-2019-106283
PMCID: PMC8474559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.PMID 31784483Read ↗

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s diseaseSemantic proximity Read ↗

Disease‑Modifying Trials in Parkinson’s Disease: Challenges, Lessons, and Future DirectionsSemantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease.Semantic proximity Read ↗

Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization studySemantic proximity Read ↗

A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design.Semantic proximity Read ↗

Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.Semantic proximity Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease.Semantic proximity Read ↗

Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study.Semantic proximity Read ↗

Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma α-Synuclein and Parkinson's Disease.Semantic proximity Read ↗

Lessons for clinical trial design in Friedreich's ataxia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.